Constellate Proteomics has closed a pre-seed round that includes €150,000 in convertible financing from Tech Scout Venture Fund and Imec.istart, and plans a €1.9 million funding round in 2027.
Credit: this report is based on a story first published by IO+. Read the original at ioplus.nl.
As reported by IO+, Delft-based Constellate Proteomics has closed a pre-seed round for its antibody quality control platform. TU Delft spun the company out in February 2026, and it is led by CEO Carlos de Lannoy together with Arian Khoshchin and Dennis de Beeld.
The deal
The pre-seed round includes €150,000 in convertible financing from Tech Scout Venture Fund and Imec.istart. Graduate Ventures and Delft Enterprises B.V. joined later, according to IO+.
Constellate plans to use the money to speed up commercialisation, including the development of a compact benchtop instrument with disposable cartridges. The company is also eyeing a €1.9 million funding round in 2027 to scale its operations and technology.
What the platform does
The company's RAYmAb platform runs four quality analyses (titer, glycosylation, aggregation and charge variant) on a tiny, untreated sample of the liquid in which cells were grown, and returns results in minutes. IO+ reports that traditional antibody quality control methods take weeks of specialised work.
The system fixes antibodies to a glass surface with reversible affinity probes and reads them with a single-molecule microscope. IO+ reports that it detects antibodies at concentrations 1,000 times lower than the current industry standard method, and that its titer readings land within 8% of the true value 19 times out of 20.
The technology rests on two core patents developed at Delft University of Technology and licensed by Constellate.
Pilots and expansion
Constellate is running unpaid pilot projects with potential customers in China, Switzerland, Germany, Sweden, Spain and the United States. Its goal is to convert three to five of those pilots into paying contracts within a year, and to grow throughput from 100 samples a day to more than 1,000.
The company is also opening a second location at BioVille in Diepenbeek, Belgium, as part of the Imec.istart Summer 2026 cohort. Its roadmap includes assays for two further quality characteristics, with an immediate focus on biopharma and possible later uses in disease diagnostics and academic research.
Original source: IO+, "TU Delft spinout lands €150K to speed up antibody testing"
